Literature DB >> 31827980

In Vitro and Ex Vivo Models for Functional Testing of Therapeutic Anti-scarring Drug Targets in Keloids.

Jyoti R Sharma1, Maribanyana Lebeko1, Elvis B Kidzeru1,2, Nonhlanhla P Khumalo1, Ardeshir Bayat1,3.   

Abstract

Significance: Keloids are benign fibro-proliferative raised dermal lesions that spread beyond the original borders of the wound, continue to grow, rarely regress, and are the most common in pigmented individuals after an abnormal wound healing response. The current treatment failure and respective challenges involved highlighting the underlying issue that the etiopathogenesis of keloids is still not well understood. Disease models are required to better understand the disease pathogenesis. It is not possible to establish keloids in animals because of the uniqueness of this disease to human skin. To address this challenge, along these lines, non-animal reproducible models are vital in investigating molecular mechanisms of keloid pathogenesis and therapeutics development. Recent Advances: Various non-animal models have been developed to better understand the molecular mechanisms involved in keloid scarring and aid in identifying and evaluating the therapeutic potential of novel drug candidates. In this scenario, the current review aims at describing in vitro monocultures, co-cultures, organotypic cultures, and ex vivo whole skin keloid tissue organ culture models. Critical Issues and Future Directions: Current treatment options for keloids are far from securing a cure or preventing disease recurrence. Identifying universally accepted effective therapy for keloids has been hampered by the absence of appropriate disease model systems. Animal models do not accurately mimic the disease, thus non-animal model systems are pivotal in keloid research. The use of these models is essential not only for a better understanding of disease biology but also for identifying and evaluating novel drug targets. Copyright 2019, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  ex vivo; in vitro; keloid scarring and/or disease; organ culture; organotypic; scar models

Year:  2019        PMID: 31827980      PMCID: PMC6904937          DOI: 10.1089/wound.2019.1040

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  2 in total

1.  Differential responses to folic acid in an established keloid fibroblast cell line are mediated by JAK1/2 and STAT3.

Authors:  Katelyn J McCann; Manoj Yadav; Mohammadali E Alishahedani; Alexandra F Freeman; Ian A Myles
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

2.  WNT5A drives interleukin-6-dependent epithelial-mesenchymal transition via the JAK/STAT pathway in keloid pathogenesis.

Authors:  Young In Lee; Jung Eun Shim; Jihee Kim; Won Jai Lee; Jae Woo Kim; Kee Hyun Nam; Ju Hee Lee
Journal:  Burns Trauma       Date:  2022-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.